Maze Therapeutics (MAZE) Long-Term Investments (2025 - 2026)
Maze Therapeutics (MAZE) posted Long-Term Investments of $10.6 million for Q1 2026, down 41.72% sequentially from $18.1 million in Q4 2025.
Powered by 
Analysis
Maze Therapeutics (MAZE) Long-Term Investments (2025 - 2026) Analysis & Trends
Maze Therapeutics has reported Long-Term Investments for 2 years, with the latest figure at $10.6 million in Q1 2026.
- Quarterly Long-Term Investments changed N/A year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (changed N/A YoY) and the FY2025 annual result came in at $18.1 million, changed N/A from the prior year.
- Long-Term Investments declined to $10.6 million in Q1 2026 per MAZE's latest filing, from $18.1 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $18.1 million in Q4 2025 and troughed at $10.6 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Maze Therapeutics | 1.55 Bn | 1.55 Bn | - | 83.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 83.82 Mn |
| Mar 31, 2026 | 10.56 Mn |
| Dec 31, 2025 | 18.11 Mn |